LK
Therapeutic Areas
Q32 Bio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bempikibart (ADX-914) | Alopecia Areata (AA) | Phase 2 |
| ADX-096 | Complement-mediated diseases | Discovery/Preclinical |
| C3d mAb fusions | Complement-mediated diseases | Discovery/Preclinical |
| Complement-targeting nanobodies | Complement-mediated diseases | Discovery/Preclinical |